MiNK Therapeutics Stock (NASDAQ:INKT)
Previous Close
$0.50
52W Range
$0.46 - $1.90
50D Avg
$0.69
200D Avg
$0.85
Market Cap
$20.72M
Avg Vol (3M)
$43.36K
Beta
0.05
Div Yield
-
INKT Company Profile
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DAWN | Day One Biopharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| INZY | Inozyme Pharma, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| IKNA | Ikena Oncology, Inc. |
| ADAP | Adaptimmune Therapeutics plc |
| AFMD | Affimed N.V. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| CADL | Candel Therapeutics, Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| FBRX | Forte Biosciences, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ALVR | AlloVir, Inc. |